ehanis:mcM eleitvecs nseogrte rtporece tmldooaur (SERM) tath scta as an snanioagtt on hte teoensgr seoctprer of eht rtsaeb nad acst as an traipla gnaoist on rneegots rpestcore in bnoe nad .teuurs eThr,eefro ↑ rski of learitonemd cnaecr dna ↑ iksR of nierteu araocms
eU:ss RE or PR vitpsoie orstum ea)stb(r
Whole point of administering a SERM after breast cancer is to reduce risk of recurrence. Increased estrogen exposure is associated with increased risk of breast cancer (per FA 2019 p. 636). So you're looking for something that is an estrogen antagonist at the breast, which narrows it down to B and C right off the bat.